COURT-RULING ·Filed Jul 28, 2026

NVS

NOVARTIS AG
NEUTRAL
Impact 1/10
Horizonimmediate Processed2mo ago CourtView Ruling on CourtListener
Court ruling (district)
Actionable Insight • Neutral

This is a routine procedural order with no price impact. Monitor for future substantive rulings (e.g., claim construction, summary judgment, or trial) that could affect Novartis's patent positions or financial exposure.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
NVS ▲ +0.08% at T+20d
NEUTRAL call ✓ call won +0.08% · α vs SPY -3.30% · entry $159.85 → $159.98
Next anchor: T+60d in 18d
Latest observation: T+45 -8.78% FF3 residual α
Entry anchored
Jul 27, 03:59 PM ET
via exchange tick
T+1d
-0.64%
call -0.64% · α +0.90%
$158.83
settled 2mo ago
T+5d
-3.87%
call -3.87% · α -6.14%
$153.67
settled 2mo ago
T+20d
+0.08%
call +0.08% · α -3.30%
$159.98
settled 6w ago
T+60d
—
call — · α —
—
in 18d

Price Chart

Loading chart...

Executive Summary

A federal district court in the Northern District of California issued a routine order granting pro hac vice admission for an attorney representing Novartis Pharmaceuticals Corp. in a patent case (Regents of University of Michigan et al v. Novartis Pharmaceuticals Corporation). This is a purely procedural step with no ruling on the merits, damages, or injunctive relief. The ruling has no material impact on Novartis AG's business or stock.

Court Ruling Details

Ruling Date
Jul 28, 2026
Court
United States District Court for the Northern District of California
Court Level
District
Case Type
patent
Ruling Type
other
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • Order granted pro hac vice admission for plaintiff's attorney; no substantive ruling on liability or damages.
  • Case is a patent infringement dispute involving Regents of University of Michigan against Novartis Pharmaceuticals Corp.

Financial Impact

Not specified

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
50% bullish (34 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-68f552434d-NVS
9 reports for NVS
Performance horizon
100% Hit rate 5 of 5 directional calls best @ T+60▲ +6.86%Jul 1, 2026
Filters
Rows
Reports for NVS — sortable, filterable
TypeNow
Sep 4, 2026
27d ago
6-K
BEARISH ★ 6/10
$137.70 $138.62▼ −0.67%▼ −1.79%$140.06 (−1.71%)
Sep 1, 2026
4w ago
6-K
BULLISH ★ 7/10
$161.25 $137.48▼ −14.74%▼ −14.82%$140.06 (−13.14%)
Aug 4, 2026
8w ago
Court Ruling
NEUTRAL ★ 2/10
$153.27 $154.61▲ +0.87%▲ +0.97%$140.06 (−8.62%)
Jul 28, 2026
9w ago
Court Ruling
NEUTRAL ★ 1/10
$159.85 $153.67▼ −3.87%▼ −6.14%$140.06 (−12.38%)
Jul 21, 2026
10w ago
6-K
NEUTRAL ★ 4/10
$153.87 $156.11▲ +1.46%▲ +2.68%$140.06 (−8.98%)
Jul 1, 2026
13w ago
Court Ruling
BEARISH ★ 5/10
$154.14 $157.03▼ −1.87%▼ −1.61%$140.06 (+9.13%)
Apr 30, 2026
22w ago
Court Ruling
BEARISH ★ 6/10
$147.85 $148.36▼ −0.34%▲ +1.38%$140.06 (+5.27%)
Apr 14, 2026
24w ago
Court Ruling
BEARISH ★ 6/10
$153.38 $147.97▲ +3.53%▲ +4.92%$140.06 (+8.68%)
Mar 30, 2026
26w ago
Court Ruling
NEUTRAL ★ 3/10
$150.36 $151.22▲ +0.57%▼ −3.73%$140.06 (−6.85%)
Showing 9 of 9

US Market Status

Market Open — Closes in 3h 35m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access